GO:0045796 negative regulation of intestinal cholesterol absorption: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045796 describes any process that stops, prevents, or reduces the uptake of cholesterol from the intestine into the blood.
• Intestinal cholesterol absorption is a multistep process involving bile acid solubilization, brush-border transport, and intracellular trafficking.
• Key genes include NPC1L1, ABCG5/ABCG8, ACAT2, MTTP, and FXR, which regulate sterol uptake and efflux.
• Gut microbiota and bile acid signaling (e.g., FXR-FGF15/19 axis) are major regulators of this process.
• Dysregulation of intestinal cholesterol absorption contributes to hypercholesterolemia, atherosclerosis, and metabolic syndrome.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of this pathway.
Description
Cholesterol homeostasis depends on a balance between intestinal absorption, endogenous synthesis, and biliary excretion. GO:0045796, negative regulation of intestinal cholesterol absorption, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of cholesterol uptake from the intestine into the blood. This biological process is critical for maintaining plasma cholesterol levels and is a target for therapeutic intervention in cardiovascular disease. The intestinal enterocyte is the primary site of cholesterol absorption, where dietary and biliary cholesterol are solubilized by bile acids and taken up via specific transporters. Understanding the negative regulation of this process is essential for developing strategies to lower cholesterol and treat metabolic disorders.
negative regulation of intestinal cholesterol absorption At A Glance
| GO ID | GO:0045796 |
|---|---|
| GO term | negative regulation of intestinal cholesterol absorption |
| Ontology | biological_process |
| Synonym | down regulation of cholesterol absorption, down-regulation of cholesterol absorption, downregulation of cholesterol absorption, inhibition of cholesterol absorption |
| Major function | Inhibition of cholesterol uptake from the intestine into the blood |
| Related processes | Cholesterol homeostasis, bile acid metabolism, lipid absorption |
| Key regulators | NPC1L1, ABCG5/ABCG8, FXR, FGF15/19, gut microbiota |
| Disease relevance | Hypercholesterolemia, atherosclerosis, metabolic syndrome |
What Is GO:0045796?
GO:0045796 is defined as any process that stops, prevents, or reduces the frequency, rate or extent of uptake of cholesterol into the blood by absorption from the intestine. In other words, it encompasses molecular and cellular events that inhibit the transfer of cholesterol from the intestinal lumen into the bloodstream, thereby limiting systemic cholesterol exposure.
Why Is negative regulation of intestinal cholesterol absorption Important in Cell Biology?
Negative regulation of intestinal cholesterol absorption is a central mechanism for controlling plasma cholesterol levels. Excessive intestinal cholesterol uptake contributes to hypercholesterolemia and atherosclerosis, major causes of cardiovascular disease. Elucidating the molecular players that inhibit this process can reveal new drug targets and biomarkers. Moreover, the interplay between gut microbiota, bile acids, and host transporters highlights the importance of this process in metabolic health.
• Controls systemic cholesterol levels and cardiovascular risk.
• Influences bile acid metabolism and enterohepatic circulation.
• Modulated by gut microbiota and FXR signaling.
• Target for cholesterol-lowering drugs (e.g., ezetimibe).
• Dysregulation linked to obesity and metabolic syndrome.
• Involved in intestinal immune responses and lipid absorption.
• Genetic variants in NPC1L1 and ABCG5/8 affect absorption efficiency.
• Provides therapeutic opportunities for atherosclerosis.
• Key for understanding diet-microbiome-host interactions.
• Essential for developing precision medicine approaches.
What Happens During negative regulation of intestinal cholesterol absorption?
Bile Acid Solubilization and Micelle Formation
In simple terms: Bile acids help dissolve cholesterol so it can be absorbed.
Dietary and biliary cholesterol must be solubilized into mixed micelles by bile acids before uptake. Negative regulation can occur by altering bile acid composition or reducing micelle formation. For example, gut microbiota can modify bile acids, reducing tauro-beta-muricholic acid, an FXR antagonist, thereby affecting cholesterol absorption.
Brush-Border Transport and NPC1L1
In simple terms: NPC1L1 is the main gatekeeper for cholesterol entry into intestinal cells.
NPC1L1 (Niemann-Pick C1-like 1) mediates cholesterol uptake at the apical membrane of enterocytes. Negative regulation of this step can involve reduced NPC1L1 expression or activity. T cell cholesterol transport has been linked to intestinal immune responses and dietary lipid absorption, suggesting immune regulation of NPC1L1 function.
Intracellular Trafficking and Esterification
In simple terms: Once inside, cholesterol is processed and packaged for transport.
After uptake, cholesterol is esterified by ACAT2 and packaged into chylomicrons by MTTP. Negative regulation can occur by enhancing efflux or reducing esterification. Intestinal epithelial NCoR deficiency ameliorates obesity and metabolic syndrome, partly by altering lipid handling.
Basolateral Efflux and ABCG5/ABCG8
In simple terms: ABCG5 and ABCG8 pump cholesterol back into the gut lumen.
ABCG5/ABCG8 heterodimers on the apical membrane efflux sterols back into the intestinal lumen, reducing net absorption. Negative regulation of absorption can be achieved by upregulating these transporters. PXR deficiency improves high-fat diet-induced obesity via induction of FGF15, which may affect bile acid and cholesterol homeostasis.
Hormonal and Microbiota Regulation
In simple terms: Gut hormones and bacteria can dial down cholesterol uptake.
FXR activation in the intestine induces FGF15/19, which inhibits bile acid synthesis and may reduce cholesterol absorption. Gut microbiota regulates bile acid metabolism, impacting FXR signaling and cholesterol absorption. Additionally, apoE phenotype influences cholesterol metabolism regulation.
Key Genes Involved in GO:0045796 negative regulation of intestinal cholesterol absorption
The following genes and proteins are central to the negative regulation of intestinal cholesterol absorption, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPC1L1 | Apical cholesterol transporter | Target of ezetimibe; KO reduces absorption |
| ABCG5 | Sterol efflux pump | Mutations cause sitosterolemia; overexpression lowers absorption |
| ABCG8 | Sterol efflux pump | Heterodimerizes with ABCG5; KO increases absorption |
| ACAT2 | Cholesterol esterification | KO reduces chylomicron secretion |
| MTTP | Chylomicron assembly | KO abolishes lipid absorption |
| FXR (NR1H4) | Bile acid sensor | Activation induces FGF15/19, inhibits absorption |
| FGF15/19 | Enterokine | Inhibits bile acid synthesis; linked to reduced absorption |
| PXR (NR1I2) | Xenobiotic receptor | Deficiency induces FGF15, improves obesity |
| NCoR | Transcriptional corepressor | Intestinal deficiency ameliorates obesity |
| ApoE | Lipoprotein component | Phenotype affects cholesterol regulation |
| T cells | Immune cells | Cholesterol transport links to lipid absorption |
| Gut microbiota | Bile acid modifiers | Regulates FXR signaling and absorption |
| Anserine | Dipeptide | Alleviates atherosclerosis in ApoE-/- mice |
| Erpixing granules | Herbal formula | Mechanism on functional dyspepsia |
| SREBP2 | Cholesterol synthesis regulator | Indirectly affects absorption |
| LXR | Oxysterol sensor | Regulates ABCG5/8 expression |
| PPARα | Lipid sensor | Modulates bile acid metabolism |
How Is negative regulation of intestinal cholesterol absorption Regulated?
The negative regulation of intestinal cholesterol absorption is controlled by a network of nuclear receptors, gut hormones, and microbiota. FXR activation by bile acids induces FGF15/19, which suppresses bile acid synthesis and may reduce cholesterol absorption. PXR deficiency induces FGF15 expression, improving high-fat diet-induced obesity. Intestinal NCoR deficiency alters transcriptional programs, ameliorating metabolic syndrome. Gut microbiota modifies bile acids, affecting FXR antagonism and cholesterol absorption. Additionally, apoE phenotype influences cholesterol metabolism regulation.
negative regulation of intestinal cholesterol absorption and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPC1L1 | Hypercholesterolemia | Intestinal-specific KO mouse |
| ABCG5/ABCG8 | Sitosterolemia | Knock-in of human mutations |
| NCoR | Obesity/metabolic syndrome | Intestinal epithelial KO |
| PXR | Diet-induced obesity | PXR KO mouse |
| ApoE | Atherosclerosis | ApoE-/- mouse |
Hypercholesterolemia and Atherosclerosis
Impaired negative regulation of intestinal cholesterol absorption leads to elevated plasma cholesterol and increased risk of atherosclerosis. Anserine alleviates atherosclerosis in ApoE-/- mice by regulating lipid metabolism, highlighting the therapeutic potential of targeting absorption. Antilipemic agents, including ezetimibe, inhibit NPC1L1 to reduce cholesterol uptake.
Metabolic Syndrome and Obesity
Intestinal epithelial NCoR deficiency ameliorates obesity and metabolic syndrome, partly by altering cholesterol absorption and lipid handling. PXR deficiency improves high-fat diet-induced obesity via FGF15 induction. These findings link negative regulation of cholesterol absorption to systemic metabolic health.
Gut Microbiota and Immune Interactions
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption, suggesting that immune cells can influence cholesterol uptake. Gut microbiota regulates bile acid metabolism, reducing FXR antagonism and affecting cholesterol absorption. This axis is relevant to inflammatory bowel diseases and metabolic disorders.
From negative regulation of intestinal cholesterol absorption-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X inhibit cholesterol absorption? | Intestinal-specific knockout |
| Does a point mutation alter transporter function? | CRISPR point mutation knock-in |
| Can overexpression reduce absorption? | Transgenic overexpression |
| How does a tag affect protein localization? | Tagged knock-in |
| What is the role of a regulatory element? | CRISPR interference/activation |
| Can a drug target the pathway? | Pharmacological intervention in KO |
How to Study the negative regulation of intestinal cholesterol absorption Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Dual-isotope assay | Cholesterol absorption rate | In vivo KO studies |
| RNA-seq | Transcriptome changes | Gene expression profiling |
| Western blot | Protein levels | Validation of KO/overexpression |
| Lipidomics | Lipid species | Metabolic profiling |
| 16S rRNA sequencing | Microbiota composition | Microbiome studies |
| Immunohistochemistry | Protein localization | Tissue distribution |
| CRISPR screening | Gene function | Identify novel regulators |
Intestinal Cholesterol Absorption Assays
Dual-isotope plasma ratio method or fecal sterol balance can measure cholesterol absorption in vivo. These assays are used to evaluate the effect of genetic manipulations.
Gene Expression Analysis
RNA-seq and qPCR can quantify expression of NPC1L1, ABCG5/8, and other genes in intestinal tissues. This helps identify transcriptional changes under negative regulation.
Protein and Lipid Profiling
Western blotting, immunohistochemistry, and lipidomics can assess protein levels and lipid species. These methods reveal post-transcriptional regulation and metabolic changes.
Microbiome and Metabolomics
16S rRNA sequencing and bile acid metabolomics can uncover microbiota-driven regulation of cholesterol absorption.
How CRISPR Can Be Used to Study GO:0045796 negative regulation of intestinal cholesterol absorption
Knockout
CRISPR knockout of candidate genes (e.g., NPC1L1, ABCG5) in intestinal cell lines or mouse models can determine their role in cholesterol absorption. Intestinal epithelial NCoR knockout ameliorates obesity, demonstrating the power of this approach.
Point Mutation
Point mutations can mimic human variants (e.g., in ABCG5/8) to study their impact on transporter function and cholesterol absorption.
Knock-in
Knock-in of tagged proteins (e.g., GFP-NPC1L1) allows live-cell imaging and localization studies. Knock-in of human disease mutations into mouse models can replicate human phenotypes.
Overexpression
Overexpression of negative regulators (e.g., ABCG5/8) can reduce cholesterol absorption and protect against atherosclerosis. Transgenic models are valuable for therapeutic target validation.
How EDITGENE Supports negative regulation of intestinal cholesterol absorption Research
Researchers studying negative regulation of intestinal cholesterol absorption-related genes often need to determine whether a candidate gene is causally involved in the pathway. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of intestinal cholesterol absorption research.
Frequently Asked Questions About negative regulation of intestinal cholesterol absorption
What is GO:0045796?
GO:0045796 is the Gene Ontology term for negative regulation of intestinal cholesterol absorption, describing processes that reduce cholesterol uptake from the intestine into the blood.
What genes are involved in negative regulation of intestinal cholesterol absorption?
Key genes include NPC1L1, ABCG5, ABCG8, ACAT2, MTTP, FXR, and FGF15/19.
How is intestinal cholesterol absorption regulated?
It is regulated by bile acids, nuclear receptors (FXR, PXR), gut hormones (FGF15/19), and gut microbiota.
What diseases are associated with impaired negative regulation of intestinal cholesterol absorption?
Hypercholesterolemia, atherosclerosis, and metabolic syndrome are linked to dysregulation of this process.
What is the role of NPC1L1 in cholesterol absorption?
NPC1L1 is the primary transporter for cholesterol uptake at the apical membrane of enterocytes.
How does gut microbiota affect cholesterol absorption?
Gut microbiota modifies bile acids, altering FXR signaling and cholesterol absorption.
What experimental models are used to study this process?
Knockout mice, intestinal cell lines, and CRISPR-edited models are commonly used.
What is the function of ABCG5/ABCG8?
They efflux sterols back into the intestinal lumen, reducing net cholesterol absorption.
How can CRISPR help study negative regulation of cholesterol absorption?
CRISPR enables knockout, point mutation, knock-in, and overexpression to dissect gene function.
What is the therapeutic potential of targeting this pathway?
Inhibiting cholesterol absorption can lower plasma cholesterol and reduce atherosclerosis risk.
Conclusion
GO:0045796, negative regulation of intestinal cholesterol absorption, is a critical biological process with profound implications for cardiovascular and metabolic health. Understanding its molecular mechanisms and key genes offers opportunities for therapeutic intervention. EDITGENE provides advanced CRISPR tools to accelerate research in this field.
References
- 1. Gao Y et al.. 2025. T cell cholesterol transport links intestinal immune responses to dietary lipid absorption.. Science 390(6769):eadt4169 PMID: 41066556
- 2. Unknown. 2012. Antilipemic Agents.. PMID: 31643276
- 3. Sayin SI et al.. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.. Cell Metab 17(2):225-35 PMID: 23395169
- 5. Hou S et al.. 2024. Intestinal epithelial cell NCoR deficiency ameliorates obesity and metabolic syndrome.. Acta Pharm Sin B 14(12):5267-5285 PMID: 39807334
- 6. Zhao LY et al.. 2017. Pregnane X receptor (PXR) deficiency improves high fat diet-induced obesity via induction of fibroblast growth factor 15 (FGF15) expression.. Biochem Pharmacol 142:194-203 PMID: 28756207
- 7. Miettinen TA. 1991. Impact of apo E phenotype on the regulation of cholesterol metabolism.. Ann Med 23(2):181-6 PMID: 2069794
- 8. Luo J et al.. 2025. Anserine alleviates atherosclerosis in ApoE(-/-) mice by regulating lipid metabolism.. J Sci Food Agric 105(15):8574-8585 PMID: 40735873
